NOV 3

Drug Profile

NOV 3

Alternative Names: NOV3

Latest Information Update: 17 Sep 2015

Price : $50

At a glance

  • Originator MorphoSys; Novartis
  • Developer Novartis
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Unspecified

Most Recent Events

  • 30 Jun 2015 Phase II clinical trials in Undefined indication in Germany (MorphoSys Interim Report, June 2015)
  • 11 May 2011 Phase-II clinical trials in Undefined indication in Germany (unspecified route)
  • 29 Jul 2010 Antibody is still in phase I trials for Undefined indication in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top